Egypt, once top Hep C sufferer, draws cure seekers

September 10, 2017
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

Like millions in Egypt, Ahmed Nada suffered silently from Hepatitis C. But the country is turning from the world's most afflicted by the disease to a global destination for those seeking a cure.

Nada, 31, only learned that he carried the virus when he tried to donate blood.

"At first I was very angry," he said. "I kept thinking whether it was from my previous work as a dentist, or from the barber or from what? I didn't know."

Previously, a Hepatitis C infection, even when diagnosed, would have gone untreated or simply been managed.

But a cheap new drug produced in Egypt since 2015 and a government programme to eliminate the condition meant Nada could be easily cured.

He registered on a government website and was directed to the nearest centre.

Now cured along with more than 1.3 million other Egyptians, Nada says the entire process was simple "from the moment I filled in the application".

Egypt has the highest prevalence of Hepatitis C infection in the world, an epidemic that started with a government programme for mass vaccinations with unsterilised syringes in the 1950s.

Seven percent of people aged between 15 and 59 have an active infection, according to Egypt's 2015 Demographics and Health Surveys.

40,000 deaths a year

The blood-borne virus can cause serious damage to the liver before being detected, and can be fatal.

About 20 percent of those who become infected get better without treatment, but the rest can remain infected for up to 30 years without showing symptoms.

"Just about every family in Egypt is touched by Hepatitis C," World Health Organization official Dr Henk Bekedam wrote in a 2014 report on the disease, which the agency said was killing about 40,000 Egyptians a year.

Since 2006, Egypt has carried out surveys to determine the epidemic's spread and negotiated cheaper drugs from abroad.

However, its first breakthrough came when the US-based Gilead Sciences pharmaceutical company developed Sovaldi, a approved by the US Food and Drug Administration in 2013.

Egypt negotiated a deal to reduce the price of a course of treatment from $84,000 (70,000 euros), or $1,000 a pill, to a fraction of that.

The National Committee for Control of Viral Hepatitis set up a website so sufferers could access the drug.

"The first day we had 100,000 , the second day 100,000 patients registered, and the following week 50,000 patients daily," said Manal Hamdy el-Sayed, a founding member of the committee running the programme.

No more waiting lists

"People were waiting impatiently," she said.

The next breakthrough came in 2015 when Egypt began to manufacture the drug locally, reducing the price for the full course to just $83, the committee's executive director Kadry al-Saeed said.

Waiting lists for the cure ended in July 2016, and the government is now searching for an estimated three million Egyptians who carry the virus without knowing it, Saeed said.

Now an Egyptian company has capitalised on the low cost of the cure locally to attract patients from abroad, where the drug is seen as exorbitantly priced.

Tour N' Cure treats visiting patients for about eight percent of the treatment's cost abroad.

"We treat patients in almost all countries," said Mostafa el-Sayed, the campaign's managing director.

The company says $7,000 covers flights, a week's accommodation, blood tests and treatment—and five days of tourism in Egypt.

Patients return home with the remainder of the medicine while Egyptian doctors follow up with them.

Mirel Damboiu, 59, from Romania, heard about the treatment through his daughter and son-in-law.

"The treatment was successful from the first five days," said Damboiu.

"In Romania this treatment is not available to buy," while another treatment available there would have been "very invasive", he said.

Damboiu will have his final round of treatment in September before undergoing final tests.

Explore further: WHO urges global push to treat hepatitis C (Update)

Related Stories

WHO urges global push to treat hepatitis C (Update)

April 9, 2014
The World Health Organization called Wednesday for a dramatic increase in screening and treatment of hepatitis C, saying higher demand would help drive down the cost of drugs for the disease.

FDA approves hep C drugs for kids 12 and older

April 7, 2017
(HealthDay)—The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C infection in children aged 12 and older.

EU nations join forces against 'exorbitant' hepatitis C drug: France

July 10, 2014
France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Egyptians design 'faster, cheaper' hepatitis C test

March 14, 2012
The American University in Cairo said Wednesday that a team of its researchers has designed a faster and cheaper test for all types of hepatitis C, which it says affects about 10 million Egyptians.

US approves pricey new pill against hepatitis C

October 10, 2014
US regulators on Friday approved Harvoni, a daily pill to treat hepatitis C that is simpler to administer than long-standing treatments but that carries a steep price tag.

New combo pill offers hope to hepatitis C patients who fail other treatment

June 1, 2017
(HealthDay)—A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report.

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Shakescene21
not rated yet Sep 11, 2017
So a course of Solvaldi pills costs $84,000 in the USA and $83 in Egypt. No wonder health insurance is unaffordable for many Americans.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.